Abstract:Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable efficacy in relapsed/refractory (r/r) B cell malignancies, including in pediatric patients with acute lymphoblastic leukemia (ALL). Expanding this success to other hematologic and solid malignancies is an area of active research and, although challenges remain, novel solutions have led to significant progress over the past decade. Ongoing clinical trials for CAR T cell therapy for T cell malignancies and acute myeloid leukemia (AML) have highlighted challenges, including antigen specificity with off-tumor toxicity and persistence concerns. In T cell malignancies, notable challenges include CAR T cell fratricide and prolonged T cell aplasia, which are being addressed with strategies such as gene editing and suicide switch technologies. In AML, antigen identification remains a significant barrier, due to shared antigens across healthy hematopoietic progenitor cells and myeloid blasts. Strategies to limit persistence and circumvent the immunosuppressive tumor microenvironment (TME) created by AML are also being explored. CAR T cell therapies for central nervous system and solid tumors have several challenges, including tumor antigen heterogeneity, immunosuppressive and hypoxic TME, and potential for off-target toxicity. Numerous CAR T cell products have been designed to overcome these challenges, including "armored" CARs and CAR/T cell receptor (TCR) hybrids. Strategies to enhance CAR T cell delivery, augment CAR T cell performance in the TME, and ensure the safety of these products have shown promising results. In this manuscript, we will review the available evidence for CAR T cell use in T cell malignancies, AML, central nervous system (CNS), and non-CNS solid tumor malignancies, and recommend areas for future research.

Comparative toxicity of feeding dried urban sludge and an equivalent amount of cadmium to swine.

[Progress in Clinical Studies of Chimeric Antigen Receptor Engineered T Cells for Treatment of Childhood Cancer].

CAR T-cells for pediatric solid tumors: where to go from here?

Prospects and challenges for use of CAR T cell therapies in solid tumors

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes

Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment

CAR-T Cells in the Treatment of Nervous System Tumors

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

CAR T cells redirected to B7-H3 for pediatric solid tumors: Current status and future perspectives

CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer

INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults

CAR T cells for solid tumors – developments to watch in 2023

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon

Development of CAR T cells designed to improve antitumor efficacy and safety

From bench to bedside: the history and progress of CAR T cell therapy

Current Clinical Application of the CAR-T Cell Therapy

CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma